A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital | Zendy

Fabien Garnier | Zendy; Delphine Chainier | Zendy; Timothy R. Walsh | Zendy; Åsa Karlsson | Zendy; Anne Bolmström | Zendy; Carole Grélaud | Zendy; M Mounier | Zendy; François Denis | Zendy; Marie-Cécile Ploy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital

Author(s) -

Fabien Garnier,

Delphine Chainier,

Timothy R. Walsh,

Åsa Karlsson,

Anne Bolmström,

Carole Grélaud,

M Mounier,

François Denis,

Marie-Cécile Ploy

Publication year - 2005

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dki413

Subject(s) - glycopeptide , staphylococcus aureus , microbiology and biotechnology , medicine , methicillin resistant staphylococcus aureus , micrococcaceae , vancomycin , antibacterial agent , antibiotics , biology , bacteria , genetics

Glycopeptides are the drugs of choice to treat infections due to methicillin-resistant Staphylococcus aureus, but since 1995, glycopeptide-intermediate S. aureus (GISA) and heterogeneous GISA (hGISA) have been reported worldwide. Detection of reduced susceptibility to glycopeptides in S. aureus is very difficult in a routine clinical laboratory. The aim of this study was to investigate the prevalence of hGISA/GISA strains using a three-step approach during a 1 year period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research